Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,755.42 +200.38 (+0.30%) CMC Crypto 200
1,425.40 -3.17 (-0.22%)
SUPN Jun 2024 24.000 call
| Previous close | 2.7000 |
| Open | 2.7000 |
| Bid | 2.6000 |
| Ask | 5.2000 |
| Strike | 24.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.7000 - 2.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireSupernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET at the Marriott Marquis Hotel in New York City. Investors
ZacksDo Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.
- GlobeNewswire
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from the planned interim analysis of the exploratory open-label Pha
